It has been reported that SEMA3B-AS1 was deemed as a novel cancer suppressor in gastric cardia adenocarcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma (37–39). Here, SEMA3B is linked to hepatocellular carcinoma.